Bone Health in Type 1 Diabetes

Completed

• Conditions: Type 1 Diabetes; Osteoporosis

• Registration Number: NCT00651196
• Lead Sponsor: Creighton University

Brief Summary

An increased skeletal fracture risk in diabetes has only recently been recognized. This human study is designed to elucidate the effect of Type 1 diabetes on bone remodeling and on structure.

Detailed Description

An increased skeletal fracture risk in diabetes has only recently been recognized. Human studies of patients with diabetes using bone mineral density and bone markers have noted low bone mass and mixed results on remodeling activity. Mouse models of diabetes have suggested that low bone turnover is the underlying problem. Low bone turnover could lead to an accumulation of microdamage that is not repaired causing compromised bone strength. Low bone turnover has not yet been confirmed in humans. This human study is designed to elucidate the effect of Type 1 diabetes on 1) bone remodeling, including histomorphometric and biochemical measures of bone formation and resorption, and 2) on structure, including micro architectural arrangement of trabeculae and bone mineral density.

Study Timeline

• Study Start: 2008-01
• Study First Submitted: 2008-03-30
• Study First Submitted QC: 2008-04-01
• Study First Posted: 2008-04-02
• Primary Completion: 2013-01
• Study Completion: 2013-01
• Status Verified: 2013-03
• Last Update Submitted: 2013-03-14
• Last Update Posted: 2013-03-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Age > 19 yrs or < 50 yrs.
• The diabetic subjects must have a diagnosis of Type 1 diabetes clinically defined as diabetes onset before age 50, acute presentation or diabetic ketoacidosis, with normal BMI. If history is equivocal, GAD antibodies > 1.45 U/mL will be used to define diagnosis.
• Diabetic subjects must be on insulin treatment.
• All subjects must have BMI between 18-30

Exclusion Criteria

• On any medications that are known to interfere with bone metabolism including loop diuretics, steroids, anticonvulsants, bisphosphonates, metformin, glitazones
• Have normal or only mildly impaired kidney function defined as a calculated GFR greater than 60 mL/min/1.73m2
• History of cancer other than skin cancer
• Unstable angina, myocardial infarction, uncontrolled hypertension, malabsorption, active rheumatoid or collagen disease.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
histomorphometry measurements	at 2nd visit

Secondary Outcome Measures

Name	Time	Method
peripheral QCT measurements	at 1st visit
micro CT measurements	at 2nd visit
nanoindentation measurements	at 2nd visit
Bone mineral density	at 1st visit

Trial Locations

Locations (1)

Creighton University; 🇺🇸 Omaha, Nebraska, United States